126 related articles for article (PubMed ID: 3224162)
1. Steady state relative bioavailability and pharmacokinetics of oral propranolol in black and white North Americans.
Sharoky M; Perkal M; Turner R; Lesko LJ
Biopharm Drug Dispos; 1988; 9(5):447-56. PubMed ID: 3224162
[TBL] [Abstract][Full Text] [Related]
2. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration.
Sowinski KM; Lima JJ; Burlew BS; Massie JD; Johnson JA
Br J Clin Pharmacol; 1996 Sep; 42(3):339-46. PubMed ID: 8877025
[TBL] [Abstract][Full Text] [Related]
3. Racial differences in propranolol pharmacokinetics.
Johnson JA; Burlew BS
Clin Pharmacol Ther; 1992 May; 51(5):495-500. PubMed ID: 1587062
[TBL] [Abstract][Full Text] [Related]
4. The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs.
Yu LX; Straughn AB; Faustino PJ; Yang Y; Parekh A; Ciavarella AB; Asafu-Adjaye E; Mehta MU; Conner DP; Lesko LJ; Hussain AS
Mol Pharm; 2004; 1(5):357-62. PubMed ID: 16026005
[TBL] [Abstract][Full Text] [Related]
5. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
[TBL] [Abstract][Full Text] [Related]
6. Effects of sensory (teasing) exposure to food on oral propranolol bioavailability.
Power JM; Morgan DJ; McLean AJ
Biopharm Drug Dispos; 1995 Oct; 16(7):579-89. PubMed ID: 8785381
[TBL] [Abstract][Full Text] [Related]
7. Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects.
Shiga T; Fujimura A; Tateishi T; Ohashi K; Ebihara A
J Clin Pharmacol; 1993 Aug; 33(8):756-61. PubMed ID: 8408738
[TBL] [Abstract][Full Text] [Related]
8. A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.
Watson RG; Bastain W; Larkin KA; Hayes JR; McAinsh JA; Shanks RG
Br J Clin Pharmacol; 1987 Oct; 24(4):527-35. PubMed ID: 3689632
[TBL] [Abstract][Full Text] [Related]
9. Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state.
Lalonde RL; Pieper JA; Straka RJ; Bottorff MB; Mirvis DM
Eur J Clin Pharmacol; 1987; 33(3):315-8. PubMed ID: 3691620
[TBL] [Abstract][Full Text] [Related]
10. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
11. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers.
Bano G; Raina RK; Zutshi U; Bedi KL; Johri RK; Sharma SC
Eur J Clin Pharmacol; 1991; 41(6):615-7. PubMed ID: 1815977
[TBL] [Abstract][Full Text] [Related]
12. The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects.
Shiga T; Fujimura A; Tateishi T; Ohashi K; Ebihara A
Eur J Clin Pharmacol; 1993; 44(5):489-92. PubMed ID: 8359189
[TBL] [Abstract][Full Text] [Related]
13. Nonlinear pharmacokinetics of unbound propranolol after oral administration.
Straka RJ; Lalonde RL; Pieper JA; Bottorff MB; Mirvis DM
J Pharm Sci; 1987 Jul; 76(7):521-4. PubMed ID: 3668812
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of propranolol hydrochloride tablet formulations: application of multiple dose crossover studies.
Eldon MA; Kinkel AW; Daniel JE; Latts JR
Biopharm Drug Dispos; 1989; 10(1):69-76. PubMed ID: 2923962
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability.
Mansur AP; Avakian SD; Paula RS; Donzella H; Santos SR; Ramires JA
Braz J Med Biol Res; 1998 May; 31(5):691-6. PubMed ID: 9698776
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in pharmacokinetics of oral propranolol in healthy Chinese volunteers.
Xie HG; Chen X
Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):468-70. PubMed ID: 8701771
[TBL] [Abstract][Full Text] [Related]
17. The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.
McCourty JC; Silas JH; Tucker GT; Lennard MS
Br J Clin Pharmacol; 1988 Mar; 25(3):349-57. PubMed ID: 3358897
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation.
Marino MR; Dey M; Garg DC; Jallad NS; Dorick DM; Martinez JJ; Weidler DJ
J Clin Pharmacol; 1987 Nov; 27(11):885-91. PubMed ID: 3429696
[TBL] [Abstract][Full Text] [Related]
19. Differences in stereoselective disposition of propranolol do not explain sensitivity differences between white and Chinese subjects: correlation between the clearance of (-)- and (+)-propranolol.
Zhou HH; Wood AJ
Clin Pharmacol Ther; 1990 Jun; 47(6):719-23. PubMed ID: 2357866
[TBL] [Abstract][Full Text] [Related]
20. Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: Hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels.
Stoschitzky K; Lindner W; Egginger G; Brunner F; Obermayer-Pietsch B; Passath A; Klein W
Clin Pharmacol Ther; 1992 Apr; 51(4):445-53. PubMed ID: 1563214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
